var data={"title":"Oxycodone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxycodone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6701?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxycodone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxycodone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=oxycodone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxycodone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50847601\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709186\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Oxycodone exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing oxycodone and monitor all patients regularly for the development of these behaviors or conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression may occur with use of oxycodone. Monitor for respiratory depression, especially during initiation of oxycodone or following a dose increase. Instruct patients to swallow oxycodone tablets whole; crushing, chewing, or dissolving oxycodone ER tablets can cause rapid release and absorption of a potentially fatal dose of oxycodone.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental ingestion:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental ingestion of even one dose of oxycodone, especially by children, can result in a fatal overdose of oxycodone.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of oxycodone during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cytochrome P450 3A4 interaction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concomitant use of oxycodone with all cytochrome P450 (CYP-450) 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used CYP3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving oxycodone and any CYP3A4 inhibitor or inducer.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of oxycodone and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of medication errors (oral solution):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ensure accuracy when prescribing, dispensing, and administering oxycodone oral solution. Dosing errors due to confusion between mg and mL, and other oxycodone oral solutions of different concentrations can result in accidental overdose.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204903\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Oxaydo;</li>\n      <li>Oxecta [DSC];</li>\n      <li>OxyCONTIN;</li>\n      <li>Roxicodone;</li>\n      <li>Xtampza ER</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204904\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Oxycodone CR;</li>\n      <li>Apo-Oxycodone CR;</li>\n      <li>Oxy.IR;</li>\n      <li>OxyNEO;</li>\n      <li>PMS-Oxycodone;</li>\n      <li>PMS-Oxycodone CR;</li>\n      <li>Supeudol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204935\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Opioid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204907\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b> Oral: <b>Note:</b> All doses should be titrated to appropriate effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Immediate release:</i> Initial: 5 to 15 mg every 4 to 6 hours as needed; dosing range: 5 to 20 mg per dose (APS 2008). For severe chronic pain, administer on a regularly scheduled basis, every 4 to 6 hours, at the lowest dose that will achieve adequate analgesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Extended release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Oxycodone ER capsules are not bioequivalent to ER tablets. Dose of ER capsules is expressed as oxycodone base and the dose of ER tablets is expressed as oxycodone hydrochloride. Oxycodone ER 60 mg and 80 mg tablets are intended for use in opioid-tolerant patients only. Single doses &gt;40 mg (ER tablets) or &gt;36 mg (ER capsules), or a total dose of &gt;80 mg daily (ER tablets) or &gt;72 mg daily (ER capsules) are for use only in opioid-tolerant patients. Opioid tolerance is defined as: Patients already taking at least morphine 60 mg orally daily, oxymorphone 25 mg orally daily, transdermal fentanyl 25 mcg per hour, oxycodone 30 mg orally daily, hydromorphone 8 mg orally daily, hydrocodone 60 mg orally daily or an equivalent dose of another opioid for at least 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Opioid naive (use as the first opioid analgesic or use in patients who are not opioid tolerant): Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ER tablet: 10 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ER capsules: 9 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from other oral oxycodone formulations to oxycodone ER: Initiate oxycodone ER with 50%of the total daily oral oxycodone daily dose (mg/day) administered every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from other opioids to oxycodone ER: Discontinue all other around-the-clock opioids when oxycodone ER is initiated. Initiate with 10 mg (ER tablets) or 9 mg (ER capsules) every 12 hours. Substantial interpatient variability exists due to patient specific factors, relative potency of different opioids, and dosage forms; therefore, it is preferable to underestimate the initial 24 hour oral oxycodone requirements and utilize rescue medication (immediate-release opioid).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from transdermal fentanyl patch to oxycodone ER: Note: Remove fentanyl patch at least 18 hours prior to starting oxycodone ER. The manufacturer suggests using the conservative conversion factor of oxycodone ER tablets 10 mg or oxycodone ER capsules 9 mg every 12 hours for each fentanyl 25 mcg/hour transdermal patch; systematic assessment of this suggested conversion has not been completed; monitor patients closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from methadone to oxycodone ER: Close monitoring is required when converting methadone to another opioid. Ratio between methadone and other opioid agonists varies widely according to previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Maintenance dose:</b> Dosage adjustment (titration): After initiation of oxycodone ER, adjust dose in increments (25% to 50%) no more frequently than every 1 to 2 days until desired pain control. Recommended maximum dose of ER capsules is 288 mg/day. Patients may require rescue doses of an immediate-release analgesic during dose titration. Observe for signs and symptoms of opioid withdrawal or signs of over sedation/toxicity; if unacceptable adverse reactions occur, the subsequent dose may be reduced. <b>Note: </b>Some clinicians have reported that in certain chronic pain patients, more frequent dosing (ie, every 8 hours) is required for effective pain relief (Gallagher 2007; Marcus 2004; Nicholson 2006), although dosing more frequently than every 12 hours is not recommended by the manufacturer, and safety and efficacy has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage adjustment for concomitant therapy:</b> Concomitant CNS depressants: Initiate oxycodone ER with 33% to 50% of the calculated recommended dose. If reduced dose is less than smallest available dosage form consider alternative analgesic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation of therapy: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Decrease dose by 25% to 50% every 2 to 4 days; monitor carefully for signs/symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both. Do not abruptly discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release: </i>Gradually titrate dose downward to prevent withdrawal signs/symptoms. Do not abruptly discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in debilitated patients (nonopioid tolerant): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Initial: There are no specific dosage adjustments provided in the manufacturer's labeling; use caution and with a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> Initial: Initiate oxycodone ER with 33% to 50% of the calculated recommended dose. If reduced dose is less than smallest available dosage form consider alternative analgesic.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204921\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=oxycodone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxycodone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b> Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Moderate to severe pain (off-label use):</b> <i>Immediate release:</i> Initial dose: 0.1 to 0.2 mg/kg/dose (moderate pain) or 0.2 mg/kg/dose (severe pain) (APS 2008). For severe chronic pain, administer on a regularly scheduled basis, every 4 to 6 hours, at the lowest dose that will achieve adequate analgesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe pain requiring around-the-clock long-term opioid therapy:</b> <i>Extended release tablets:</i> <b>Note:</b> Use only in pediatric patients &ge;11 years of age who are already receiving opioid therapy for at least 5 consecutive days, tolerating a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent at least for the two days immediately prior to starting oxycodone ER, and for which alternative treatment options are inadequate. Prior to initiation of oxycodone ER, all other around-the-clock opioid therapy must be discontinued. Extended-release capsules are not approved for use in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: Children &ge;11 years and Adolescents: Oral: Initial dose based on current opioid regimen dose; use the conversion factor table to convert from the current opioid(s) daily dose to the oxycodone ER daily dose according to the following equation. <b>Note:</b> Substantial interpatient variability exists due to patient specific factors, relative potency of different opioids, and dosage forms; therefore, it is preferable to underestimate the initial 24 hour oral oxycodone requirements and utilize rescue medication (immediate-release opioid):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose of oxycodone ER administered every 12 hours = (mg/day of current opioid regimen X conversion factor)/2</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dose calculations or adjustments for specific clinical scenarios:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If rounding is necessary, numerical value should be rounded <b>down</b> to the nearest tablet strength. If calculated dose is &lt;20 mg, do not start oxycodone ER as there is no safe tablet strength available.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If more than one opioid in the regimen, calculate the approximate oxycodone dose for each opioid and sum the totals for the approximate oxycodone ER <b>daily</b> dose, then divided by 2 for the every 12 hours oxycodone ER dose.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If current opioid regimen includes a fixed-dose opioid/nonopioid dosage form (eg, hydrocodone/acetaminophen), only the mg of opioid should be used in the conversion calculations.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If patient receiving concomitant CNS depressants, initiate oxycodone ER with 33% to 50% of the calculated recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If using asymmetric dosing, the higher dose should be scheduled as the morning dose, and the lower dose 12 hours later.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> The following conversion table should ONLY be used to convert opioid doses to oxycodone ER tablets (not from oxycodone ER to other opioids; it is NOT a table of equianalgesic doses as it may overestimate initial dose).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Conversion Factor for Calculating Initial Oxycodone ER Tablet Dose in Pediatric Patients &ge;11 years</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Current opioid regimen to be converted to oxycodone ER tablet</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Conversion Factor</p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>For patients receiving high-dose parenteral opioids, a more conservative conversion factor should be applied (ie, lower numerical conversion factor); for example, for high-dose parenteral morphine, a conversion of 1.5 should be used for calculations instead of 3.</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Oral</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Parenteral<sup>1</sup></b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxycodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydrocodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.9</p></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydromorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Morphine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Tramadol</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.17</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.2</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:2em;\">\n      <i>Conversion from fentanyl patch to oxycodone ER:</i> Limited data available: <b>Note:</b> Remove fentanyl patch at least 18 hours prior to starting oxycodone ER. Initial dose based on current opioid regimen dose; the manufacturer suggests using the conservative conversion factor of oxycodone ER 10 mg every 12 hours for each fentanyl 25 mcg/hour transdermal patch; systematic assessment of this suggested conversion has not be completed; monitor patients closely</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Dosage adjustment (titration): After initiation of oxycodone ER, adjust dose in small increments (up to 25%) no more frequently than every 1 to 2 days until desired pain control; patients may require rescue doses of an immediate-release analgesic during dose titration. Observe for signs and symptoms of opioid withdrawal or signs of over sedation/toxicity; if unacceptable adverse reactions occur, the subsequent dose may be reduced.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204908\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Initiate therapy at low end of dosing range and use caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11347464\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;60 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Oxycodone clearance may decrease in patients with renal impairment; initiate therapy at low end of dosing range.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;60 mL/minute: Serum concentrations are increased ~50%. Initiate at the low end of the dosage range (use caution); adjust dose as clinically indicated. Alternatively, for both immediate- and extended-release forms, doses of 33% to 50% of usual initial dosing have been recommended (Oxy IR Canadian product labeling; OxyNeo Canadian product labeling). For ER tablets and capsules, if the reduced dose is less than smallest available dosage form, consider alternative analgesic.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204909\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Immediate release</i> (Adults): Initiate therapy at 33% to 50% the usual dosage and titrate carefully.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Extended release tablets</i> (Children &ge;11 years, Adolescents, and Adults) or <i>Extended release capsules</i> (Adults): Initial: Initiate oxycodone ER with 33% to 50% of the calculated recommended dose. If reduced dose is less than smallest available dosage form consider alternative analgesic.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204880\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule ER 12 Hour Abuse-Deterrent, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xtampza ER: 9 mg (100 ea); 13.5 mg (100 ea); 18 mg (100 ea); 27 mg (100 ea); 36 mg (100 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (15 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (5 mL, 15 mL, 473 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roxicodone: 5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roxicodone: 15 mg [scored; contains fd&amp;c blue #2 (indigotine), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roxicodone: 30 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Abuse-Deterrent, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxaydo: 5 mg, 7.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxecta: 5 mg [DSC], 7.5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet ER 12 Hour Abuse-Deterrent, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">OxyCONTIN: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">OxyCONTIN: 80 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204864\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46945076\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xtampza ER: Strength is expressed in terms of oxycodone base. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">9 mg equivalent to 10 mg oxycodone hydrochloride</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">13.5 mg equivalent to 15 mg oxycodone hydrochloride</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">18 mg equivalent to 20 mg oxycodone hydrochloride</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">36 mg equivalent to 40 mg oxycodone hydrochloride</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29243245\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oxy IR: 5 mg, 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Supeudol: 5 mg, 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet Controlled Release, Oral, as hydrochloride</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OxyNeo: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50305220\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">RoxyBond: FDA approved April 2017; availability anticipated in 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204937\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10162706\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oxaydo: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf#page=26&amp;token=Y83bm3ok86s6UKZnHzdt8+mZFZIyf2u4TYWKxIEsBRN2SZ74HfYFT0OhzDiV2gLGql+aR/cKPAx9j/hy4VFMhrUDUB06Nh3pg2VHqjZS2GP4B7q+0Cij0Ylt5Gb4GBOH&amp;TOPIC_ID=9729\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf#page=26</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oxycodone hydrochloride capsules: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/200534s006lbl.pdf#page=30&amp;token=1KY4I+vgQ1FhIZd3dNTuePZNmAj2g1LUPgbkegnozNMLoYnwH0GGAGjGPdeGgrBlElILbgEKrT5ubm6FzmQkSAW547+hHErD/N4rWpKzXTkx0hrswzkQHV0sFsu729pO&amp;TOPIC_ID=9729\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/200534s006lbl.pdf#page=30</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oxycodone hydrochloride oral solution: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201194s002lbl.pdf#page=29&amp;token=D1WpFJmKPg+vBiDz9GJKuH4aaIsm+t/HK35Cy3uY8Fq5OQgOaSOoAvYwmJRjTajkrAO2EFegaVLacRw6+wyGK/4EHE1dCinLzVgQFn15aLA+oCWGl3wPj3pB5qUI4isM&amp;TOPIC_ID=9729\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201194s002lbl.pdf#page=29</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OxyContin: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208530.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68V3WFaMi5sONRqbq26b64eQ==&amp;TOPIC_ID=9729\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208530.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Roxybond: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209777lbl.pdf#page=43&amp;token=4xLf/Q6p79so9dC41J8Mqx7Oxa0RtiLDpKwiIx3nu92S3dObcFHi6/ZgQG74fkfDu5/96lPb8BSGVFPQ5l8YgF+Kcdt8Kf0VsIO9vWm4A2nRZIMhvN0EpCSsLnr714qt&amp;TOPIC_ID=9729\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209777lbl.pdf#page=43</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Roxicodone: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021011s006lbl.pdf#page=26&amp;token=DeSntLw+52irIEAfzfz1fcRNLcdNfk2lQc7lbOQ549L2nEvtTrQduWCQK81c/jjZBlFC6I5Dx/v6UnZdR5RUyXVhfDHwyKjnRu0N2N3ef1ogFGMDnOLsA5RqejrKNvj7&amp;TOPIC_ID=9729\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021011s006lbl.pdf#page=26</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Xtampza ER: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208090s003lbl.pdf#page=35&amp;token=WeW+CXdaxrfrGK9tlwCsaZKzU5elq+RwBGSOEzrKFpIJbMA67jmFdIoYm67wBRz+1y8rdgYrtDnjzHzpIbS5yBYtRE37TNixpr4dfb7kC7TWU83W2vBJxpOvmmIBsB2X&amp;TOPIC_ID=9729\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208090s003lbl.pdf#page=35</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204884\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Appropriate laxatives should be administered to avoid the constipating side effects associated with use. Antiemetics may be needed for persistent nausea. Some dosage forms may not be appropriate for administration through feeding tubes (eg, gastric, NG). Refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release dosage forms:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Administer with or without food. Swallow tablet whole. Do not moisten, dissolve, cut, crush, break, or chew extended release tablets. Extended release tablets should be administered one at a time and each followed with water immediately after placing in the mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Administer each dose with food and approximately the same amount. For patients with difficulty swallowing, capsule may be opened and the contents sprinkled on soft foods (eg, applesauce, pudding, yogurt, ice cream, jam) or into a cup for administration directly into the mouth. Rinse mouth immediately afterwards to ensure all contents have been swallowed. Contents of capsule may also be administered through a nasogastric (NG) tube or gastrostomy tube (G-tube). Flush tube with water first, then pour capsule contents directly into tube (do not premix capsule contents with fluid that will be used to flush them through the tube). After contents have been placed in tube, flush tube with 15 mL of water, milk, or liquid nutritional supplement once and then repeat twice with 10 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release dosage forms:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Administer with or without food. Available in two strengths; 1 mg/mL and a concentrated oral solution (20 mg/mL). Precautions should be taken to avoid confusion between the different concentrations; prescriptions should have the concentration specified as well as the dose clearly represented as milligram (mg) of oxycodone, not volume (mL). The enclosed calibrated oral syringe should always be used to administer the concentrated oral solution to ensure the dose is measured and administered accurately. The concentrated oral solution (20 mg/mL) should only be used in opioid-tolerant patients (taking &ge;30 mg/day of oxycodone or equivalent for &ge;1 week).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Without abuse deterrent:</i> Administer with or without food. When administered with food, onset may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>With abuse deterrent:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Oxaydo</i>: Administer with or without food. Do not crush, chew, or dissolve the tablets. Due to inactive ingredient that causes nasal burning (upon snorting) and throat irritation, the tablet must be swallowed whole with enough water to ensure complete swallowing immediately after placing in the mouth. The tablet should not be wet prior to placing in the mouth.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204883\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate-release formulations: Management of acute or chronic moderate to severe pain where the use of an opioid analgesic is appropriate and for which alternative treatments are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release formulations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in adults and opioid-tolerant pediatric patients &ge;11 years of age who are already receiving and tolerating a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Reserve oxycodone for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Oxycodone ER is not indicated as an as-needed analgesic.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204943\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">OxyCODONE may be confused with HYDROcodone, OxyCONTIN, oxyMORphone </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">OxyCONTIN may be confused with MS Contin, oxybutynin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">OxyFast may be confused with Roxanol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roxicodone may be confused with Roxanol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204871\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (adults: 23%; Xtampza ER: 9%; children and adolescents 11 to 16 years: 1% to &lt;5%), headache (children and adolescents 11 to 16 years: 14%; Xtampza ER: 14%), dizziness (children &ge;11 years, adolescents, and adults: 9% to 13%; Xtampza ER: 2% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (children &ge;11 years, adolescents, and adults: 6% to 13%; Xtampza ER: 3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (children &ge;11 years, adolescents, and adults: 15% to 23%; Xtampza ER: 11% to 17%), constipation (adults: 23%; Xtampza ER: 5% to 13%; children and adolescents 11 to 16 years: 9%), vomiting (children &ge;11 years, adolescents, and adults: 12% to 21%; Xtampza ER: 4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children &ge;11 years, adolescents, and adults: 1% to 11%; Xtampza ER: 1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (&lt;1% [including facial and peripheral]; Xtampza ER: 1% to 5%), flushing (Xtampza ER: 1% to 5%), hypertension (Xtampza ER: 1% to 5%), orthostatic hypotension (1% to 5%), decreased oxygen saturation (children and adolescents 11 to 16 years: 1% to &lt;5%), tachycardia (children and adolescents 11 to 16 years: 1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal dreams (1% to 5%; Xtampza ER: &lt;1%), abnormality in thinking (1% to 5%), anxiety (children &ge;11 years, adolescents, and adults: 1% to 5%; Xtampza ER: 1% to 5%), chills (children and adolescents 11 to 16 years: 1% to 5%; Xtampza ER: 1% to 5%), confusion (1% to 5%), drug withdrawal (Xtampza ER: 1% to 5%), dysphoria (1% to 5%), euphoria (1% to 5%; Xtampza ER: &lt;1%), fatigue (children and adolescents 11 to 16 years: 1% to 5%; Xtampza ER: 1% to 5%), insomnia (children &ge;11 years, adolescents, and adults: 1% to 5%; Xtampza ER: 1% to 5%), irritability (Xtampza ER: 1% to 5%), lethargy (children and adolescents 11 to 16 years: 1% to &lt;5%; Xtampza ER: &lt;1%), migraine (&lt;1%; Xtampza ER: 1% to 5%), nervousness (1% to 5%), twitching (1% to 5%), withdrawal syndrome (&lt;1%; Xtampza ER: 1% to 5%), agitation (children and adolescents: 1% to &lt;5%; adults: &lt;1%), depression (children and adolescents: 1% to &lt;5%; adults: &lt;1%), hypoesthesia (children and adolescents: 1% to &lt;5%; adults: &lt;1%), pain (children and adolescents 11 to 16 years: 1% to &lt;5%), paresthesia (children and adolescents: 1% to &lt;5%; adults: &lt;1%), procedural pain (children and adolescents 11 to 16 years: 1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (5%), excoriation (Xtampza ER: 1% to 5%), hyperhidrosis (Xtampza ER: 1% to 5%; children and adolescents 11 to 16 years: 1% to &lt;5%), skin rash (children &ge;11 years, adolescents, and adults: 1% to 5%; Xtampza ER: 1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (Xtampza ER: 1% to 5%), hypochloremia (children and adolescents 11 to 16 years: 1% to &lt;5%), hyponatremia (children and adolescents 11 to 16 years: 1% to &lt;5%), weight loss (children and adolescents 11 to 16 years: 1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (6%), diarrhea (children &ge;11 years, adolescents, and adults: 1% to 6%; Xtampza ER: 1% to 5%), decreased appetite (children and adolescents 11 to 16 years: 5%; Xtampza ER: 1% to 5%), abdominal pain (children &ge;11 years, adolescents, and adults: 1% to 5%; Xtampza ER: 1% to 5%), anorexia (1% to 5%), dyspepsia (1% to 5%), gastritis (1% to 5%), gastroesophageal reflux disease (children and adolescents 11 to 16 years: 1% to 5%; Xtampza ER: 1% to 5%), hiccups (1% to 5%), upper abdominal pain (Xtampza ER: 1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria (children and adolescents: 1% to &lt;5%; adults: &lt;1%), urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hemoglobin (children and adolescents 11 to 16 years: 1% to &lt;5%), decreased neutrophils (children and adolescents 11 to 16 years: 1% to &lt;5%), decreased platelet count (children and adolescents 11 to 16 years: 1% to &lt;5%), decreased red blood cells (children and adolescents 11 to 16 years: 1% to &lt;5%), febrile neutropenia (children and adolescents 11 to 16 years: 1% to &lt;5%), neutropenia (children and adolescents 11 to 16 years: 1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (children and adolescents 11 to 16 years: 1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (children &ge;11 years, adolescents, and adults: 1% to 6%), arthralgia (Xtampza ER: 1% to 5%), back pain (Xtampza ER: 1% to 5%), musculoskeletal pain (Xtampza ER: 1% to 5%; children and adolescents 11 to 16 years: 1% to &lt;5%), myalgia (Xtampza ER: 1% to 5%), tremor (&lt;1%; Xtampza ER: 1% to 5%), limb pain (children and adolescents 11 to 16 years: 1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (Xtampza ER: 1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (&lt;1%; Xtampza ER: 1% to 5%), dyspnea (1% to 5%; Xtampza ER: &lt;1%), oropharyngeal pain (Xtampza ER: 1% to 5%; children and adolescents 11 to 16 years: 1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Seroma (children and adolescents 11 to 16 years: 1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure, thrombophlebitis, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Neuralgia, personality disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin photosensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gout</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gingivitis, glossitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, hemorrhage, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthritis, laryngospasm, neck pain, ostealgia, pathological fracture</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis, epistaxis, pharyngitis, pulmonary disease, respiratory depression, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports (any population): Abnormal gait, abnormal stools (tablet in stool [some controlled release dosage forms]; Anderson 2002), aggressive behavior, amenorrhea, amnesia, anaphylactoid reaction, anaphylaxis, chest pain, choking sensation (due to properties of controlled release tablets), cholestasis, cough, dehydration, dental caries, depersonalization, depression of ST segment on ECG, disturbed sleep, diverticulitis (exacerbation), drug abuse, drug dependence, dysgeusia, dysphagia (or other swallowing difficulties due to properties of controlled release tablets), emotional lability, eructation, exfoliative dermatitis, flatulence, gag reflex (due to properties of controlled release tablets), hallucination, hematuria, histamine release, hyperalgesia, hyperkinesia, hypertonia, hypogonadism (Brennan 2013; Debono 2011), hyponatremia, hypotonia, impotence, increased appetite, increased gamma-glutamyl transferase, increased heart rate, increased intracranial pressure, increased liver enzymes, increased thirst, intestinal obstruction, lymphadenopathy, malaise, memory impairment, mood changes, neonatal withdrawal, night sweats, palpitations, pharyngeal edema, polyuria, restlessness, seizure, SIADH, speech disturbance, stomatitis, stupor, suicidal ideation, suicidal tendencies, syncope, tinnitus, urticaria, vasodilatation, vertigo, visual disturbance, voice disorder, xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204887\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis, angioedema) to oxycodone or any component of the formulation; significant respiratory depression; hypercarbia; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to other opioids; suspected surgical abdomen (eg, acute appendicitis or pancreatitis); any disease/condition that affects bowel transit; mild pain that can be managed with other pain medications (immediate release); mild, intermittent or short duration pain that can be managed with other pain medications or acute pain (extended release); chronic obstructive airway; status asthmaticus; cor pulmonale; acute alcoholism; delirium tremens; convulsive disorders; severe CNS depression; increased cerebrospinal or intracranial pressure; head injury; monoamine oxidase (MAO) inhibitors (concomitant use or within 14 days of therapy); pregnant women or during labor and delivery; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204868\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: May cause constipation which may be problematic in patients with unstable angina and patients post-myocardial infarction. Consider preventive measures (eg, stool softener, increased fiber) to reduce the potential for constipation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxymorphone).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Swallow ER tablets whole; crushing, chewing, or dissolving can cause rapid release and a potentially fatal dose.</b> Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenocortical insufficiency, including Addison disease; dose adjustment may be required. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; may cause constriction of sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; oxycodone clearance may decrease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture; dose adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; oxycodone clearance may decrease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with a history of seizure disorders; may cause or exacerbate preexisting seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: <b>[US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of oxycodone and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP 3A4 interactions: <b>[US Boxed Warning]: Use with all CYP3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitant CYP 3A4 inducer may result in increased oxycodone concentrations. Monitor patients receiving oxycodone and any CYP 3A4 inhibitor or inducer. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Dose reduction may be required. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Use opioids for chronic pain with caution in this age group; monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</b> Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. Onset, duration and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablets: Tablets may be difficult to swallow and could become lodged in throat; patients with swallowing difficulties may be at increased risk. Cases of intestinal obstruction or diverticulitis exacerbation have also been reported, including cases requiring medical intervention to remove the tablet; patients with an underlying GI disease (eg, esophageal cancer, colon cancer) may be at increased risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solutions: <b> [US Boxed Warning]: Ensure accuracy when prescribing, dispensing, and administering oxycodone oral solution. Dosing errors due to confusion between mg and mL, and other oxycodone oral solutions of different concentrations can results in accidental overdose.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: <b>[US Boxed Warning]: Use exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient&rsquo;s risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk for misuse include younger age, concomitant depression (major), and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental exposure: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially in children, can result in a fatal overdose of oxycodone.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should <b>not</b> be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg, NSAIDs, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and non-opioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages. Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Opioids decrease bowel motility; monitor for decreased bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Taper dose gradually when discontinuing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204929\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204873\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9729&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: OxyCODONE may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: Seek alternatives when possible. Avoid use of oxycodone/naltrexone during and within 14 days after monoamine oxidase inhibitor treatment. Non-US labeling for some oxycodone products states that such use is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of OxyCODONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of OxyCODONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May enhance the adverse/toxic effect of OxyCODONE. Voriconazole may increase the serum concentration of OxyCODONE. Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204890\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Oxycodone crosses the placenta (Kokki 2012). Maternal use of opioids may be associated with birth defects, poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2016]). If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur (Chou 2009). Symptoms of neonatal abstinence syndrome (NAS) following opioid exposure may be autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness/abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning) (Dow 2012; Hudak 2012). Mothers who are physically dependent on opioids may give birth to infants who are also physically dependent. Opioids may cause respiratory depression and psycho-physiologic effects in the neonate; newborns of mothers receiving opioids during labor should be monitored.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Agents other than oxycodone are commonly used to treat maternal pain during labor and immediately postpartum (ACOG 177 2017) as well as chronic noncancer pain in pregnant women or those who may become pregnant (CDC [Dowell 2016]; Chou 2009; Kahan 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11347295\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Oxycodone is present in breast milk in variable concentrations.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In one study, oxycodone was measurable in breast milk up to 37 hours after the last maternal dose and therapeutic concentrations were detected in the serum of a breastfeeding infant (Seaton 2007). Oxycodone was also detected in the urine of a breastfed infant (Sulton-Villavasso 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">CNS depression, constipation, decreased feeding, and respiratory distress/irregular breathing have been observed in infants exposed to oxycodone via breast milk (Lam 2012; Sulton-Villavasso 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines note that nonopioid analgesics are preferred for postpartum pain in breastfeeding women (Montgomery 2012). When an opiate is needed, use of oxycodone in breastfeeding women is not recommended by some guidelines (Sachs 2013). Other guidelines note it may be useful to treat pain in some postpartum women, although prolonged and frequent use may cause neonatal sedation (Montgomery 2012). Maternal doses greater than 30 mg/day are not recommended (ACOG 177 2017). In addition, caution should be used in a woman who may be an ultrarapid metabolizer; oxycodone is a substrate for CYP2D6 and their breastfeeding infants may be at higher risk for adverse events (Montgomery 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When opioids are needed in breastfeeding women, the lowest effective dose for the shortest duration of time should be used to limit adverse events in the mother and breastfeeding infant. In general, a single occasional dose of an opioid analgesic may be compatible with breastfeeding (WHO 2002). Breastfeeding women using opioids for postpartum pain or for the treatment of chronic maternal pain should monitor their infants for drowsiness, sedation, feeding difficulties, or limpness (ACOG 177 2017; Montgomery 2012; Sachs 2013). Withdrawal symptoms may occur when maternal use is discontinued or breastfeeding is stopped.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204891\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Instruct patient to avoid high-fat meals when taking some products (food has no effect on the reformulated OxyContin).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204877\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pain relief, respiratory and mental status, blood pressure; signs of misuse, abuse, and addiction; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations: Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and re-checking should be considered at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204867\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204886\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Pain relief: Immediate release: 10 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Immediate release: 0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immediate release: 3 to 6 hours; Extended release: &le;12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Children 2 to 10 years: 2.1 L/kg (range: 1.2 to 3.7 L/kg); Adults: 2.6 L/kg; distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 38% to 45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatically via CYP3A4 to noroxycodone (has weak analgesic), noroxymorphone, and alpha- and beta-noroxycodol. CYP2D6 mediated metabolism produces oxymorphone (has analgesic activity; low plasma  concentrations [&lt;15%]), alpha- and beta-oxymorphol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Extended release tablet, immediate release: 60% to 87%; Extended release capsule is not bioequivalent to extended release tablet; however AUC, is similar in a fed state</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apparent: Immediate release: 3.2 to ~4 hours; Extended release tablet: 4.5 hours; Extended release capsule: 5.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elimination: Children 2 to 10 years: 1.8 hours (range: 1.2 to 3 hours); Adults: 3.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults with CrCl &lt;60 mL/minute: Half-life increases by 1 hour, but peak oxycodone concentrations increase by 50% and AUC increases by 60%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults with mild to moderate hepatic impairment: Half-life increases by 2.3 hours, peak oxycodone concentrations increase by 50%, and AUC increases by 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Immediate release: 1.2 to 1.9 hours; Extended release: 4 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~19% as parent; &gt;64% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989443\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 12 Hour Abuse-Deterrent</b> (Xtampza ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (100): $486.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13.5 mg (100): $716.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (100): $908.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27 mg (100): $1,263.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36 mg (100): $1,555.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (OxyCODONE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $184.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (OxyCODONE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (30 mL): $218.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (OxyCODONE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (5 mL): $7.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Abuse-Deterrent</b> (Oxaydo Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $801.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $1,201.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet ER 12 Hour Abuse-Deterrent</b> (OxyCODONE HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $302.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $483.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $563.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $851.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $965.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,485.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $1,685.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet ER 12 Hour Abuse-Deterrent</b> (OxyCONTIN Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (20): $90.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (20): $133.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (20): $168.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (20): $234.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (20): $288.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (20): $409.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (20): $504.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (OxyCODONE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $54.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $62.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $189.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $110.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $358.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Roxicodone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $202.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $623.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,223.02</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204892\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abtard (GB);</li>\n      <li>Alnagon (RO);</li>\n      <li>Dancex (IE);</li>\n      <li>Endone (AU);</li>\n      <li>Epethinan (IE);</li>\n      <li>Ircodon (KR);</li>\n      <li>Lynlor (GB);</li>\n      <li>M-Oxy (PE);</li>\n      <li>Oxycod (IL);</li>\n      <li>OxyContin (AR, AT, BR, CH, CL, CN, CO, CR, CY, CZ, DK, DO, EC, EE, ES, FI, GB, GT, HK, HN, IE, IL, IT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, SE, SG, SV, VE);</li>\n      <li>Oxycontin (BB, HR, HU, IS, LU, RO, SI, SK, TR, VN);</li>\n      <li>Oxycontin CR (KR);</li>\n      <li>Oxycontin LP (FR);</li>\n      <li>Oxycontin Neo (PH);</li>\n      <li>Oxyfast (JP);</li>\n      <li>Oxygesic (DE);</li>\n      <li>Oxyneo (VN);</li>\n      <li>Oxynorm (AT, AU, BE, CH, CY, DK, ES, FI, FR, GB, HK, IE, IS, MY, NO, NZ, PH, SE, SG, TR);</li>\n      <li>OxyNorm (JP);</li>\n      <li>Oxynorm IV (SG);</li>\n      <li>Plexicodim (MX);</li>\n      <li>Proladone (AU);</li>\n      <li>Reltebon (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric Analgesia and Anesthesia,' <i>Obstet Gynecol</i>, 2002, 100(1):177-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/12100826/pubmed\" target=\"_blank\" id=\"12100826\">12100826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins&mdash;Obstetrics. Practice Bulletin No. 177: Obstetric Analgesia and Anesthesia. <i>Obstet Gynecol</i>. 2017;129(4):e73-e89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/28333819/pubmed\" target=\"_blank\" id=\"28333819\">28333819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Pain Society (APS). <i>Principles of analgesic use in the treatment of acute pain and cancer pain</i>. Sixth edition. Glenview, IL. 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson DT, Fritz KL, Muto JJ. Oxycontin: the concept of a &quot;ghost pill&quot; and the postmortem tissue distribution of oxycodone in 36 cases. <i>J Anal Toxicol</i>. 2002;26(7):448-459.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/12422999 /pubmed\" target=\"_blank\" id=\"12422999 \">12422999 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al, &quot;Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,&quot; <i>Neurology</i>, 2011, 76(20):1758-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al, &quot;Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&quot;<i> J Pain</i>, 2009, 10(2):113-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debono M, Chan S, Rolfe C, Jones TH. Tramadol-induced adrenal insufficiency. <i>Eur J Clin Pharmacol</i>. 2011; 67:865-867. Doi: 10.1007/s00228-011-0992-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow K, Ordean A, Murphy-Oikonen J, et al, &quot;Neonatal Abstinence Syndrome Clinical Practice Guidelines For Ontario,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(3):e488-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/23241498/pubmed\" target=\"_blank\" id=\"23241498\">23241498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain&mdash;United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gallagher RM, Welz-Bosna M, Gammaitoni A. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain. <i>Pain Med</i>. 2007;8(1):71-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/17244106/pubmed\" target=\"_blank\" id=\"17244106\">17244106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML, Tan RC, Committee on Drugs, et al, &quot;Neonatal Drug Withdrawal,&quot; <i>Pediatrics</i>, 2012, 129(2):e540-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/22291123/pubmed\" target=\"_blank\" id=\"22291123\">22291123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan M, Wilson L, Mailis-Gagnon A, et al, &quot;Canadian Guideline For Safe and Effective Use of Opioids For Chronic Noncancer Pain: Clinical Summary For Family Physicians. Part 2: Special Populations,&quot; <i>Can Fam Physician</i>, 2011, 57(11):1269-76, e419-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/22084456/pubmed\" target=\"_blank\" id=\"22084456\">22084456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalso E and Vainio A, &ldquo;Morphine and Oxycodone Hydrochloride in the Management of Cancer Pain,&rdquo; <i>Clin Pharmacol Ther</i>, 1990, 47(5):639-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/2188774/pubmed\" target=\"_blank\" id=\"2188774\">2188774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kokki M, Franco MG, Raatikainen K, et al. Intravenous oxycodone for pain relief in the first stage of labour--maternal pharmacokinetics and neonatal exposure. <i>Basic Clin Pharmacol Toxico</i>l. 2012;111(3):182-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/22448718/pubmed\" target=\"_blank\" id=\"22448718\">22448718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam J, Kelly L, Ciszkowski C, et al. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. <i>J Pediatr</i>. 2012;160(1):33-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/21880331/pubmed\" target=\"_blank\" id=\"21880331\">21880331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcus DA, Glick RM. Sustained-release oxycodone dosing survey of chronic pain patients. <i>Clin J Pain</i>. 2004;20(5):363-366.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/15322444/pubmed\" target=\"_blank\" id=\"15322444\">15322444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx CM, Pucino F, Carlson JD, et al. Oxycodone excretion in human milk in the puerperium. <i>Drug Intell Clin Pharm</i>. 1986;20:474.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, and Academy of Breastfeeding Medicine, &quot;ABM Clinical Protocol #15: Analgesia and Anesthesia For the Breastfeeding Mother, Revised 2012,&quot; <i>Breastfeed Med</i>, 2012, 7(6):547-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. <i>Curr Med Res Opin</i>. 2006;22(8):1503-1514.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/16870075/pubmed\" target=\"_blank\" id=\"16870075\">16870075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxaydo (oxycodone) [prescribing information]. Wayne, PA: Egalet US; December 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/16870075/pubmed\" target=\"_blank\" id=\"16870075\">16870075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    OxyContin (oxycodone) [prescribing information]. Stamford, CT: Purdue Pharma; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxycodone hydrochloride capsules [prescribing information. Philadelphia, PA: Lannett Company, Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxycodone HCl oral solution (oxycodone) [prescribing information]. Eatontown, NJ: West-Ward; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxy IR (oxycodone) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxyneo (oxycodone) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roxicodone (oxycodone) [prescribing information]. Hazelwood, MO: Mallinckrodt Pharmaceuticals; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roxybond (oxycodone) [prescribing information]. Valley Cottage, NY: Cerovene for Inspirion Delivery Sciences LLC; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seaton S, Reeves M, McLean S. Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: relationships between maternal plasma, breast milk and neonatal plasma levels. <i>Aust N Z J Obstet Gynaecol</i>. 2007;47(3):181-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/17550483/pubmed\" target=\"_blank\" id=\"17550483\">17550483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sulton-Villavasso C, Austin CA, Patra KP, et al. Index of suspicion. Case 1: Infant who has respiratory distress. Case 2: Abnormal behavior, seizures, and altered sensorium in a 7-year-old boy. Case 3: Fever and dysphagia in a 4-year-old girl. <i>Pediatr Rev</i>. 2012;33(6):279-284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/22659261/pubmed\" target=\"_blank\" id=\"22659261\">22659261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turturro MA and O'Toole KS, &ldquo;Oxycodone-Induced Pulmonary Edema,&rdquo; <i>Am J Emerg Med</i>, 1991, 9(2):201-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/1994955/pubmed\" target=\"_blank\" id=\"1994955\">1994955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xtampza ER (oxycodone) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo; <i>Ann Pharmacother</i>, 2004, 38:1525-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/15252190/pubmed\" target=\"_blank\" id=\"15252190\">15252190</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9729 Version 269.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50847601\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709186\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204903\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F204904\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F204935\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F204907\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F204921\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F204908\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F11347464\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F204909\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204880\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F204864\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46945076\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F29243245\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50305220\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F204937\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10162706\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F204884\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F204883\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F204943\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204871\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204887\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204868\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F204929\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204873\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204890\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11347295\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F204891\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F204877\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204867\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F204886\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989443\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F204892\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9729|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxycodone-patient-drug-information\" class=\"drug drug_patient\">Oxycodone: Patient drug information</a></li><li><a href=\"topic.htm?path=oxycodone-pediatric-drug-information\" class=\"drug drug_pediatric\">Oxycodone: Pediatric drug information</a></li></ul></div></div>","javascript":null}